Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07298902 · ClinicalTrials.gov registry record · NA
Non-Invasive Deep Brain Neuromodulation for Smoking Cessation
A NA study, sponsored by The University of Texas Health Science Center, Houston.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT07298902: Recruiting NA study, sponsored by The University of Texas Health Science Center, Houston.
NCT07298902 is a NA study that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07298902, a NA study, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study will develop novel low intensity focused ultrasound (LIFU) therapy to help people to quit cigarette smoking. Smoking is associated with cancers of the lung. Available smoking cessation methods help many to quit. However, for the many who continue to smoke despite the strong desire to quit and after exhausting existing therapeutic approaches, new treatment methods are needed. Without more effective treatment, many will continue to smoke, and our progress on cancer prevention through smoking cessation may decelerate as these associated cancer risks will remain. Brain imaging research has identified specific areas of the brain linked to severe nicotine addiction, but up to now there are no effective ways to directly target most of these deeper brain regions. LIFU is a new and safe method to modulate brain functions that can either inhibit overactive activity or restore normal activity levels. The purpose of this study is to provide a novel ultrasound-based neuromodulation strategy for smoking cessation in people who have difficulty to quit smoking despite numerous serious attempts in their lives. LIFU works by sending acoustic pressure modulating neural activity in the human brain.
Primary Outcome
Cigarette per day (CPD) is measured to index smoking reduction and cessation.
Interventions
- DEVICE Low intensity focused ultrasound with active stimulations
- DEVICE low intensity focused ultrasound with sham stimulations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-04-13 |
| Est. Completion | 2030-11-30 |
| Phase | NA |
What NCT07298902 shows while recruiting
NCT07298902 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Low intensity focused ultrasound with active stimulations is the first listed.
NCT07298902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07298902 about?
NCT07298902 is a clinical study titled "Non-Invasive Deep Brain Neuromodulation for Smoking Cessation". This study will develop novel low intensity focused ultrasound (LIFU) therapy to help people to quit cigarette smoking. Smoking is associated with cancers of the lung. Available smoking cessation methods help many to quit. However, for the many who continue to smoke despite the strong desire to quit...
What is the current status of trial NCT07298902?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-04-13. Estimated completion is 2030-11-30.
What interventions are being tested in trial NCT07298902?
The interventions under investigation include: Low intensity focused ultrasound with active stimulations (DEVICE), low intensity focused ultrasound with sham stimulations (DEVICE).
Who is sponsoring clinical trial NCT07298902?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07298902's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI